



**TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION  
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)**

Madrid, 8 May 2024

In compliance with the information duties provided for in article 227 of the Law 6/2023, of 17 March, on Securities Market and Investment Services, Laboratorios Farmacéuticos ROVI, S.A. (hereinafter, "**ROVI**" or the "**Company**") hereby discloses to the Spanish National Market Commission the following

**OTHER RELEVANT INFORMATION**

The Board of Directors of the Company has adopted, among others, the following resolutions:

- I.** To call shareholders to the Ordinary General Shareholders' Meeting, which is expected to be held on 24 June 2024, at 11:00 am, on first call, at calle Príncipe de Vergara 187, Plaza de Rodrigo Uría, 28002, Madrid with the following agenda:
1. Examination and approval, if applicable, of the individual annual accounts of the Company (balance sheet, income statement, statement of changes in equity, cash flow statement and notes) and of the consolidated annual accounts of the Company with its subsidiaries (consolidated balance sheet, consolidated income statement, consolidated statement of comprehensive income, consolidated statement of changes in shareholders' equity, consolidated statement of cash flows and consolidated notes to the financial statements), as well as the individual and consolidated management reports of the Company with its subsidiaries, all of them corresponding to the financial year ended 31 December 2023.

2. Examination and approval, if applicable, of the statement of non-financial information included in the consolidated management report of the Company and its subsidiaries for the financial year ended 31 December 2023.
3. Examination and approval, if applicable, of the proposed allocation of the individual results corresponding to the financial year ended 31 December 2023.
4. Examination and approval, if applicable, of the management and activity of the Board of Directors during the financial year ended 31 December 2023.
5. Examination and approval, if applicable, of the re-election of Ms. Fátima Báñez García as external independent director, for the term established in the Bylaws.
6. Examination and approval, if applicable, of the maximum annual remuneration of the members of the Board of Directors in their capacity as such for the 2024 financial year.
7. Examination and approval, if applicable, of the remuneration policy of the Board Members for the period 2025-2027.
8. Approval of the Long-Term Incentive Plan (2025-2027) through the delivery of shares of the Company, if applicable, to the executive directors of the Company.
9. Examination and approval, if applicable, of a reduction of the share capital through the cancellation of a maximum of 3,347,619 shares of treasury stock, and consequent amendment of Article 5 of the Company's Bylaws.
10. Examination and approval, if applicable, of the re-election of the auditors of the Company and its consolidated group for the 2024 financial year.

11. Delegation of powers to formalize and register the resolutions adopted by the General Shareholders' Meeting and to carry out the mandatory filing of the accounts.

CONSULTATIVE ITEM

12. Annual Company Directors' Remuneration Report.
  - II.** To propose to the General Shareholders' Meeting, among other resolutions, the distribution of a dividend of EUR 1,1037 gross per share entitled to receive it, charged to the financial year 2023 results and the non-restricted reserves allocated in the account "Results from previous financial years", as well as the a reduction of ROVI's share capital through the cancellation of treasury stock, to contribute to the remuneration of ROVI's shareholders by increasing the earnings per share.

The Company will publish in the next few days the announcement of the call of the Ordinary General Shareholders' Meeting in the terms provided by law, together with the rest of the documentation related to General Shareholders' Meeting.

Mr. Juan López-Belmonte Encina  
Chairman of the Board of Directors and Chief Executive Officer  
Laboratorios Farmacéuticos ROVI, S.A.